MATERIALS AND METHODS
candidemia, candidiasis, hepatic impairment
HEPATIC IMPAIRMENT, CANDIDEMIA, CANDIDIASIS, STERILE
This multicenter, open-label, non-comparative, single-arm study (NCT04148287), evaluated the safety and efficacy of FMGX for the treatment of candidemia and/or invasive candidiasis caused by Eligible participants (males and females, ≥ 18 years of age) had an established diagnosis of candidemia and/or invasive candidiasis caused by Mycological and clinical diagnoses criteria were: ≥ 1 positive culture from blood or other normally sterile site for Exclusion criteria included severe or moderate hepatic impairment (total bilirubin > 3x upper limit of normal and alanine aminotransferase or aspartate aminotransferase > 5x upper limit of normal); concomitant use of strong CYP inhibitors; investigator-assessed life expectancy <7 days; diagnosis of 